ConMed (NSDQ:CNMD) subsidiary SurgiQuest lost an intellectual property spat with Lexion Medical last week when a U.S. patent board invalidated a trocar patent.
SurgiQuest sued Lexion last year, alleging infringement of patent no. 9,095,372B2, covering a “system and method for improved gas recirculation in surgical trocars with pneumatic sealing,” by Lexion’s line of Insuflow Synergy Port devices.
Lexion asked the U.S. Patent Trial & Appeals Board for an inter partes review of the patent, arguing that the first 11 claims are unpatentable for obviousness.
The PTAB agreed, ruling June 29 that a person of ordinary skill in the art would have found the claims to be obvious.
Utica, N.Y.-based Conmed paid $265 million for SurgiQuest back in January 2016, inheriting its various beefs with Lexion. In April 2017, SurgiQuest lost a $12.2 million false advertising case against its rival when a jury in the U.S. District Court for Delaware found it liable for $2.2 million in compensatory damages and an additional $10 million in punitive damages for false advertising in marketing literature for its AirSeal system.
The post Patent board invalidates SurgiQuest patent in Lexion spat appeared first on MassDevice.
from MassDevice https://ift.tt/2u0rCKj
Cap comentari:
Publica un comentari a l'entrada